Hansa Biopharma provides business update incl. certain key financials ahead of the JP Morgan Global Healthcare Conference
· Commercial launch activities for Idefirix[®] progressing as planned · Patient recruitment in the two phase 2 studies in AMR and GBS was reinitiated in December 2020 · Year-end cash position of SEK 1.4 billionLund, Sweden January 11, 2021. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2020 and certain preliminary, unaudited key financials for its financial year 2020. The Company will be participating in the JP Morgan Global Healthcare Conference in San Francisco from